Breaking News

Novartis to Close Sandoz Facility

To discontinue and/or divest several generic products facing pricing pressures

Novartis plans to close a Sandoz generics manufacturing facility in Broomfield, CO that will result in the loss of approximately 450 jobs over the next couple of years. The company plans to discontinue and/or divest several products with limited growth potential, specifically those facing pricing pressures in the U.S.
 
The products include oral generic treatments in cardiology, central nervous system, endocrinology, respiratory and pain. 
 
The phased closure and transfer of some operations to a Sandoz facility in North Carolina is scheduled to be completed in late 2019.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters